(NASDAQ: CORT) Corcept Therapeutics's forecast annual revenue growth rate of 16.94% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Corcept Therapeutics's revenue in 2024 is $482,375,000.On average, 4 Wall Street analysts forecast CORT's revenue for 2024 to be $62,815,903,799, with the lowest CORT revenue forecast at $62,120,784,539, and the highest CORT revenue forecast at $63,801,906,920. On average, 4 Wall Street analysts forecast CORT's revenue for 2025 to be $68,311,848,963, with the lowest CORT revenue forecast at $63,307,093,805, and the highest CORT revenue forecast at $73,287,205,182.
In 2026, CORT is forecast to generate $81,463,319,039 in revenue, with the lowest revenue forecast at $81,357,420,751 and the highest revenue forecast at $81,582,053,483.